YOUR SEARCH FOR Text 262 RESULTS
101 of Total
Q3 2023 Incyte Corporation Earnings Conference Call | Incyte
Events Corporate Presentations Scientific Presentations Q3 2023 Incyte Corporation Earnings Conference Call Oct 31, 2023 at 8:00 AM EDT Click here
102 of Total
Q3 2024 Incyte Corporation Earnings Conference Call | Incyte
Events Corporate Presentations Scientific Presentations Q3 2024 Incyte Corporation Earnings Conference Call Oct 29, 2024 at 8:00 AM EDT Click here
103 of Total
Q3 2025 Incyte Corporation Earnings Conference Call | Incyte
Events Corporate Presentations Scientific Presentations Q3 2025 Incyte Corporation Earnings Conference Call Oct 28, 2025 at 8:00 AM EDT Click here
104 of Total
Q4 2023 Incyte Corporation Earnings Conference Call | Incyte
Events Corporate Presentations Scientific Presentations Q4 2023 Incyte Corporation Earnings Conference Call Feb 13, 2024 at 8:00 AM EST Click here
105 of Total
Q4 2024 Incyte Corporation Earnings Conference Call | Incyte
Events Corporate Presentations Scientific Presentations Q4 2024 Incyte Corporation Earnings Conference Call Feb 10, 2025 at 8:00 AM EST Click here
106 of Total
Q4/YE 2022 Incyte Corporation Earnings Conference Call | Incyte
Events Corporate Presentations Scientific Presentations Q4/YE 2022 Incyte Corporation Earnings Conference Call Feb 7, 2023 at 8:00 AM EST Click here
107 of Total
TD Cowen 46th Annual Health Care Conference | Incyte
Events Corporate Presentations Scientific Presentations TD Cowen 46th Annual Health Care Conference Mar 2, 2026 at 10:30 AM EST Click here for
108 of Total
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatm
View all news Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell
109 of Total
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advance
View all news Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the
110 of Total
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a
View all news Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse